HK1076642A1 - Recombinant poxvirus expressing homologous genes inserted into the poxviral genome - Google Patents

Recombinant poxvirus expressing homologous genes inserted into the poxviral genome

Info

Publication number
HK1076642A1
HK1076642A1 HK05108644A HK05108644A HK1076642A1 HK 1076642 A1 HK1076642 A1 HK 1076642A1 HK 05108644 A HK05108644 A HK 05108644A HK 05108644 A HK05108644 A HK 05108644A HK 1076642 A1 HK1076642 A1 HK 1076642A1
Authority
HK
Hong Kong
Prior art keywords
recombinant poxvirus
homologous genes
genes inserted
poxviral genome
poxvirus expressing
Prior art date
Application number
HK05108644A
Other languages
English (en)
Inventor
Paul Howley
Sonja Leyrer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of HK1076642A1 publication Critical patent/HK1076642A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK05108644A 2002-05-16 2005-09-29 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome HK1076642A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200752 2002-05-16
DKPA200200753 2002-05-16
PCT/EP2003/005047 WO2003097846A1 (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome

Publications (1)

Publication Number Publication Date
HK1076642A1 true HK1076642A1 (en) 2006-01-20

Family

ID=29551228

Family Applications (2)

Application Number Title Priority Date Filing Date
HK05108644A HK1076642A1 (en) 2002-05-16 2005-09-29 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
HK05108710A HK1076836A1 (en) 2002-05-16 2005-09-30 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK05108710A HK1076836A1 (en) 2002-05-16 2005-09-30 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)

Country Status (23)

Country Link
US (14) US7338662B2 (de)
EP (3) EP1506301B1 (de)
JP (4) JP4895505B2 (de)
KR (4) KR20120002627A (de)
CN (6) CN101831411A (de)
AT (1) ATE315660T1 (de)
AU (4) AU2003242540A1 (de)
BR (2) BRPI0311178B8 (de)
CA (3) CA2812019A1 (de)
DE (1) DE60303218T2 (de)
DK (2) DK1506301T3 (de)
EA (3) EA020230B1 (de)
ES (1) ES2256776T3 (de)
HK (2) HK1076642A1 (de)
IL (4) IL164172A0 (de)
MX (2) MXPA04011194A (de)
NO (3) NO334273B1 (de)
NZ (2) NZ536502A (de)
PL (2) PL218318B1 (de)
PT (1) PT1407033E (de)
SI (1) SI1407033T1 (de)
UA (1) UA82479C2 (de)
WO (2) WO2003097846A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4101327C1 (de) * 1991-01-18 1991-10-24 Mercedes-Benz Aktiengesellschaft, 7000 Stuttgart, De
CZ295808B6 (cs) * 2000-11-23 2005-11-16 Bavarian Nordic A/S Modifikovaný virus vakcinie typu Ankara
MXPA04010353A (es) * 2002-04-19 2005-03-07 Bavarian Nordic As Virus de la vaccina modificada ankara para la vacunacion de neonatos.
CN101831411A (zh) * 2002-05-16 2010-09-15 巴法里安诺迪克有限公司 表达插入痘病毒基因组中的同源基因的重组痘病毒
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
EA009008B1 (ru) * 2002-09-05 2007-10-26 Бавариан Нордик А/С Способ амплификации вируса оспы
WO2005048957A2 (en) 2003-02-20 2005-06-02 Therion Biologics Corporation Novel insertion sites in pox vectors
GB2402391A (en) * 2003-06-04 2004-12-08 Oxxon Pharmaccines Ltd Fowlpox recombinant genome
EP1807508A4 (de) * 2004-11-05 2008-03-12 Us Gov Health & Human Serv Verfahren zum aufbereiten von zellen und viren
PT1855720T (pt) * 2005-02-23 2016-12-14 Bavarian Nordic As Uso de um poxvírus modificado para a rápida indução de imunidade contra um poxvírus ou outros agentes infeciosos
EP2027271A4 (de) * 2006-05-19 2010-06-09 Glycofi Inc Rekombinante vektoren
CN103255110B (zh) * 2006-08-25 2016-04-20 美国国有健康与人类服务部(马里兰州) 修饰的安卡拉痘苗病毒基因的基因组中保守基因之间的基因间位点
US20090098529A1 (en) * 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
US8440202B2 (en) * 2006-11-09 2013-05-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
ES2637629T3 (es) * 2006-11-09 2017-10-13 The United States Of America As Represented By The Secretary Of The Navy Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo
EP2390340A3 (de) * 2007-01-30 2012-02-22 Transgene SA Papillomavirus E1 und E2-Polypeptiden mit reduziertem Identitätsanteil kodierender Vektor
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
CN101688223B (zh) * 2007-05-15 2013-07-31 特兰斯吉恩股份有限公司 用于多基因表达的载体
WO2008150404A1 (en) * 2007-05-30 2008-12-11 Wyeth Raccoon poxvirus expressing genes of feline antigens
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
WO2009052328A1 (en) * 2007-10-18 2009-04-23 Bn Immunotherapeutics Inc. Use of mva to treat prostate cancer
EP2303322A1 (de) * 2008-06-20 2011-04-06 Bavarian Nordic A/S Rekombinanter modifizierter vaccinia-virus-masern-impfstoff
KR100894430B1 (ko) * 2008-11-11 2009-04-22 시스템디엔디(주) 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법
DK2352834T3 (en) 2008-11-21 2017-03-13 Bavarian Nordic As VECTOR INCLUDING MULTIPLE HOMOLOGICAL NUCLEOTIDE SEQUENCES
JP2013507107A (ja) 2009-10-08 2013-03-04 バヴァリアン・ノルディック・アクティーゼルスカブ Ｈｉｖに対するヒトにおける広範なｔ細胞応答の生成
AU2010306559B2 (en) 2009-10-16 2015-07-16 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services . Recombinant modified vaccinia Ankara (MVA) vaccinia virus containing restructured insertion sites
WO2011087839A1 (en) 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
AU2011230491A1 (en) * 2010-03-26 2012-10-18 Emergent Product Development Gaithersburg Inc. Ectodomains of influenza Matrix 2 protein, expression system, and uses thereof
CA2802430C (en) 2010-07-20 2021-07-20 Bavarian Nordic A/S Method for harvesting poxvirus
US20120328649A1 (en) * 2010-09-23 2012-12-27 Baxter Healthcare S.A. Recombinant Viral Vectors and Methods for Inducing an Immune Response to Yellow Fever Virus
WO2012048817A2 (en) 2010-10-15 2012-04-19 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara influenza vaccine
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
EP2788021B1 (de) 2011-12-09 2017-01-18 Bavarian Nordic A/S Pockenvirus-vektor zur expression von bakteriellen antigen, welche mit tetanus toxin fragment c verbunden sind
EP2620446A1 (de) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogene zur HIV-Impfung
EP3530283A1 (de) 2012-06-05 2019-08-28 The Australian National University Impfung mit interleukin-4-antagonisten
US9480738B2 (en) 2012-08-01 2016-11-01 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
WO2014062778A1 (en) 2012-10-19 2014-04-24 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
KR102212253B1 (ko) * 2013-03-15 2021-02-04 세멘티스 리미티드 면역 조절
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
WO2014139587A1 (en) * 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
KR101645642B1 (ko) 2014-10-16 2016-08-11 대한민국 Kvac１０３ 유래의 재조합 백시니아 바이러스
KR101623498B1 (ko) 2014-10-16 2016-05-24 대한민국 약독화 백시니아 바이러스주 kvac１０３
AU2016229408A1 (en) 2015-02-25 2017-09-14 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
WO2016168862A1 (en) 2015-04-17 2016-10-20 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
KR20160140075A (ko) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
WO2016202828A1 (en) 2015-06-15 2016-12-22 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106591361A (zh) * 2015-10-20 2017-04-26 钱文斌 一种重组痘溶瘤病毒及其构建方法和应用
AU2017206102C1 (en) 2016-01-08 2022-02-10 Geovax Inc. Compositions and methods for generating an immune response to a tumor associated antigen
ES2921605T3 (es) * 2016-01-29 2022-08-30 Bavarian Nordic As Vacuna contra el virus de la encefalitis equina basada en el virus de la variolovacuna modificado Ankara (VMA) recombinante
WO2017136419A1 (en) * 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus
KR20180133395A (ko) 2016-02-25 2018-12-14 메모리얼 슬로안 케터링 캔서 센터 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스
EP3419662A4 (de) 2016-02-25 2019-09-18 Memorial Sloan Kettering Cancer Center Menschliches flt3l exprimierendes rekombinantes mva oder mvadele3l und verwendung davon als immuntherapeutika gegen solide tumoren
US10517944B2 (en) 2016-05-02 2019-12-31 Janssen Vaccines & Prevention B.V. Therapeutic HPV vaccine combinations
WO2018032057A1 (en) * 2016-08-19 2018-02-22 Sementis Limited Viral vaccines
WO2018064516A1 (en) * 2016-09-30 2018-04-05 Monsanto Technology Llc Method for selecting target sites for site-specific genome modification in plants
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
BR112019026126A2 (pt) * 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
JP2021523712A (ja) 2018-05-11 2021-09-09 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 安定性が改善された遺伝子組み換え組換えワクシニアアンカラ（ｒｍｖａ）ワクチン及びその調製方法
WO2019216929A1 (en) * 2018-05-11 2019-11-14 City Of Hope Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof
CN111979204B (zh) * 2019-05-24 2023-10-13 杭州功楚生物科技有限公司 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途
EP4058058A1 (de) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosierungsschema für impfstoffe
US20210299245A1 (en) * 2020-03-31 2021-09-30 Sementis Limited Attenuated poxvirus vector based vaccine for protection against covid-19
WO2024011250A1 (en) 2022-07-08 2024-01-11 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
JPH0795956B2 (ja) * 1986-09-22 1995-10-18 京都大学長 ポックスウイルス由来発現制御領域
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5651972A (en) 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US6893845B1 (en) * 1990-09-28 2005-05-17 Applied Molecular Evolution, Inc. Surface expression libraries of heteromeric receptors
JP3602530B2 (ja) * 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
BE1004877A3 (fr) * 1991-05-27 1993-02-16 Solvay Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus.
FR2679249B1 (fr) * 1991-07-15 1993-11-26 Centre Nal Recherc Scientifique Souches de levure avec integration stable de genes heterologues.
CA2110505A1 (en) 1991-07-26 1993-02-18 Enzo Paoletti Infectious bursal disease virus recombinant poxvirus vaccine
ATE253123T1 (de) 1991-08-26 2003-11-15 Baxter Healthcare Sa Ein intaktes fpv-tk-gen enthaltender rekombinanter virus der vogelpocken
ATE181108T1 (de) * 1991-08-26 1999-06-15 Immuno Ag Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP0753581A1 (de) 1995-07-10 1997-01-15 Immuno Ag Verbesserte rekombinante eukaryotische zytoplasmatische Viren, Methode ihrer Herstellung und ihrer Verwendung als Impfstoffe
DE19629828A1 (de) * 1996-07-24 1998-01-29 Bayer Ag Carbanilide
MY150893A (en) 1996-09-24 2014-03-14 Bavarian Nordic As Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
AUPP380598A0 (en) * 1998-05-29 1998-06-25 Commonwealth Scientific And Industrial Research Organisation Genetically manipulated entomopoxvirus
US6252871B1 (en) 1998-07-01 2001-06-26 Powerwave Technologies, Inc. Switchable combiner/splitter
US20040265324A1 (en) * 1999-03-23 2004-12-30 Cardosa Mary Jane Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
US6682742B1 (en) * 1999-05-28 2004-01-27 Gsf Forschungszentrum Fur Unwelt Und Gesundheit Gmbh Vector for integration of heterologous sequences into poxviral genomes
CN1291012C (zh) * 2000-03-14 2006-12-20 巴法里安诺迪克有限公司 修饰的安卡拉牛痘病毒(mva)的变株
CA2341356C (en) * 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
AU2001293222B2 (en) * 2000-08-29 2007-09-20 Wyeth Holdings Corporation Packaging of positive-strand RNA virus replicon particles
CZ295808B6 (cs) 2000-11-23 2005-11-16 Bavarian Nordic A/S Modifikovaný virus vakcinie typu Ankara
CN101831411A (zh) * 2002-05-16 2010-09-15 巴法里安诺迪克有限公司 表达插入痘病毒基因组中的同源基因的重组痘病毒
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
KR20050083839A (ko) * 2002-11-25 2005-08-26 버베리안 노딕 에이/에스 두개 이상의 우두 ａｔｉ 프로모터를 포함하는 재조합폭스바이러스

Also Published As

Publication number Publication date
IL193088A0 (en) 2009-02-11
NO334273B1 (no) 2014-01-27
HK1076836A1 (en) 2006-01-27
CN102719408A (zh) 2012-10-10
US20110244574A1 (en) 2011-10-06
ES2256776T3 (es) 2006-07-16
US7338662B2 (en) 2008-03-04
EP2253709A1 (de) 2010-11-24
US8435543B2 (en) 2013-05-07
EP1506301A1 (de) 2005-02-16
AU2003242540A1 (en) 2003-12-02
IL164177A0 (en) 2005-12-18
US20090311746A1 (en) 2009-12-17
AU2009200380A1 (en) 2009-02-19
US20110053260A1 (en) 2011-03-03
US20110053259A1 (en) 2011-03-03
DK1407033T3 (da) 2006-05-22
AU2009200380C1 (en) 2010-03-11
US8309326B2 (en) 2012-11-13
JP4693092B2 (ja) 2011-06-01
EA200900180A1 (ru) 2009-08-28
US20130243813A1 (en) 2013-09-19
IL193087A (en) 2012-10-31
JP2005525823A (ja) 2005-09-02
NZ536501A (en) 2006-08-31
US20120178157A1 (en) 2012-07-12
CN100494388C (zh) 2009-06-03
NO20111324A1 (no) 2011-09-29
CN1653184A (zh) 2005-08-10
KR101005630B1 (ko) 2011-01-05
EP1407033B1 (de) 2006-01-11
CN1653183A (zh) 2005-08-10
US20120039936A1 (en) 2012-02-16
KR20100110901A (ko) 2010-10-13
CA2481521A1 (en) 2003-11-27
PL372088A1 (en) 2005-07-11
EA012160B1 (ru) 2009-08-28
BRPI0311178B8 (pt) 2021-05-25
JP5777199B2 (ja) 2015-09-09
UA82479C2 (uk) 2008-04-25
EP1506301B1 (de) 2014-04-30
EA020230B1 (ru) 2014-09-30
CA2481799A1 (en) 2003-11-27
CN102703393A (zh) 2012-10-03
KR20040108809A (ko) 2004-12-24
JP2005525822A (ja) 2005-09-02
NO336489B1 (no) 2015-09-07
US7550147B2 (en) 2009-06-23
DK1506301T3 (da) 2014-07-21
US20100303856A1 (en) 2010-12-02
JP2011004755A (ja) 2011-01-13
US8414900B2 (en) 2013-04-09
IL164172A0 (en) 2005-12-18
PL216760B1 (pl) 2014-05-30
CA2481521C (en) 2012-04-17
US9109233B2 (en) 2015-08-18
DE60303218D1 (de) 2006-04-06
KR20040108798A (ko) 2004-12-24
BR0310051A (pt) 2005-02-15
BR0311178A (pt) 2005-03-29
MXPA04010713A (es) 2005-03-07
EA200401507A1 (ru) 2005-06-30
WO2003097845A1 (en) 2003-11-27
WO2003097846A1 (en) 2003-11-27
MXPA04011194A (es) 2005-02-14
ATE315660T1 (de) 2006-02-15
CN102199628A (zh) 2011-09-28
PL218318B1 (pl) 2014-11-28
IL193088A (en) 2015-02-26
KR101041691B1 (ko) 2011-06-14
EP1407033A1 (de) 2004-04-14
CA2812019A1 (en) 2003-11-27
JP2010259446A (ja) 2010-11-18
KR101138067B1 (ko) 2012-04-24
EA007811B1 (ru) 2007-02-27
AU2009200380B2 (en) 2009-10-01
AU2003236646A1 (en) 2003-12-02
AU2003236646B2 (en) 2009-01-15
SI1407033T1 (sl) 2006-06-30
US20120082696A1 (en) 2012-04-05
US8288125B2 (en) 2012-10-16
US20100173388A1 (en) 2010-07-08
US20110250693A1 (en) 2011-10-13
US8034354B2 (en) 2011-10-11
KR20120002627A (ko) 2012-01-06
JP4895505B2 (ja) 2012-03-14
NO20045480L (no) 2004-12-16
CN1653183B (zh) 2012-07-25
US20120135501A1 (en) 2012-05-31
US20060165727A1 (en) 2006-07-27
EP2253709B1 (de) 2018-04-11
EA200401506A1 (ru) 2005-04-28
IL193087A0 (en) 2009-02-11
BRPI0311178B1 (pt) 2020-11-17
US20050244428A1 (en) 2005-11-03
PT1407033E (pt) 2006-05-31
US7964374B2 (en) 2011-06-21
NO20044940L (no) 2004-11-12
US8741308B2 (en) 2014-06-03
DE60303218T2 (de) 2006-09-14
PL372093A1 (en) 2005-07-11
AU2008255213B2 (en) 2011-10-06
AU2008255213A1 (en) 2009-01-08
CA2481799C (en) 2014-01-28
CN101831411A (zh) 2010-09-15
NZ536502A (en) 2005-10-28

Similar Documents

Publication Publication Date Title
HK1076642A1 (en) Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
IL146937A (en) Method for producing a progeny library comprised of polynucleotide sequences
GB0109297D0 (en) Vaccine
CN101142319B (zh) 基于使用修饰安卡拉痘苗病毒的疫苗
ATE228016T1 (de) Lebendvakzine zur behandlung von tumorerkrankungen
DE60229962D1 (de) Verringerung der virulenz von mycobacterium tuberculosis und tuberkuloseschutz mittels inaktivierung des phop-gens
ATE268384T1 (de) Analog von haemophilus hin47 mit verminderter protease aktivität
ZA965586B (en) Coccidiosis poultry vaccine
WO2003013598A3 (en) Novel vaccine compositions and methods of vaccine preparation for veterinary and human diseases
UA104993C2 (uk) Рекомбінантний поксвірус, який експресує гомологічні гени, вставлені в поксвірусний геном
ZA200002615B (en) Live attenuated bacteria for use in a vaccine.
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
AP2003002944A0 (en) Method to generate non virulent microorganisms from pathogenic ones through permanent genetic modification of their biological membrane for vaccine production.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230513